Published in Cancer Weekly, June 27th, 2000
These initial trials were conducted at a major public hospital in Sydney, Australia, to provide data on blood level changes over time, and the tolerability of the drug in humans.
NV-06 was delivered as a single intravenous injection to a small number of cancer patients. Dr. Graham Kelly, Novogen, said the initial results are encouraging. "NV-06 behaved in the human blood stream just as predicted from pre-clinical studies," said Kelly. "The result marks an important milestone in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly